TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options Under Clinical Evaluation
Source: Childhood Craniopharyngioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: November 26, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Newly Diagnosed Childhood Craniopharyngioma
Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
Preclinical contemporary evaluations have identified active molecular and immune pathways in craniopharyngioma that may be targetable using commercially available or investigational agents. Specifically, MAPK and RAF pathways and immune/inflammatory targets such as PD-1 pathway components and IL-6 have been identified.[7,56-61][Level of evidence C1]
Source links and citations
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
NCT05465174 (Nivolumab and Tovorafenib [DAY101] for Treatment of Craniopharyngioma in Children and Young Adults): This study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF kinase (tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice